Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Japan Approves Precedex for Pediatric Use, Expands Labels for Nubeqa, Rinvoq, and More
February 27, 2023
- PMDA Reviewing 16 APIs for Paradoxical Drug Reaction
February 27, 2023
- Komeito Poised to Call for Govt Support on Meiji Pharma’s Nacubactam
February 27, 2023
- Japan Panel OKs Plan to Offer 2 Boosters for Elderly in FY2023; Program to Start from May
February 24, 2023
- Alexion’s Danicopan, Pfizer’s Elranatamab and 2 More APIs Get Orphan Tag
February 24, 2023
- Nipro Pharma Likely to Face Business Improvement Order over Violations
February 24, 2023
- MHLW Panel Maintains Caution against Xocova Use in Women Who Might Be Pregnant
February 22, 2023
- MOF to Work with Industry to Boost Drug Discovery, Minister Says on Trade Deficit
February 22, 2023
- MHLW to Launch SaMD Working Group to Compile Opinions by Summer
February 22, 2023
- Consider Special Characteristics of Patches If Govt Is to Revise LLP Pricing Rules: LDP League
February 21, 2023
- LDP Project Team Hears Report on Expert Panel Debate; Chair Voices Difficulty around Political Intervention
February 21, 2023
- LDP’s Generic League Aiming to Finalize Proposal in April for Honebuto Policy
February 21, 2023
- Avigan Used Improperly for 429 Patients in Observational Study: MHLW
February 21, 2023
- AZ’s Evusheld Gets Label Update on Repeat Dosing
February 21, 2023
- MHLW to Launch Fact-Finding Study on COVID-19 Vaccine Reactions
February 20, 2023
- Lilly’s Ulcerative Colitis Med Up for MHLW Panel Review on March 3
February 20, 2023
- Chuikyo OKs Pricing Plan for Xocova Listing, 100 Billion Yen Threshold for Possible Re-Pricing
February 16, 2023
- Generic Approval Roster Includes at Least 3 AGs; Azilva, Revlimid, Maintate
February 16, 2023
- MHLW Approves First Generics for Azilva, Revlimid towards June Listing
February 16, 2023
- Expert Panel Agrees on Need for Generic Industry Shakeup, Company Criteria Floated
February 16, 2023
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…